Inside informationEnglish
NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- Nanobiotix
- Filed
- 21/01/2025, 08:30
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- English
- AMF reference
- 114651_20250121